TILT Biotherapeutics Announces over $10 Million Financing to Advance Oncology Immunotherapy Assets

Appoints Tuija Keinonen as Chair TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it has completed the first close of its financing

Related Keywords

Guangdong ,Jilin ,China ,Helsinki ,Eteläuomen Läi ,Finland ,Finnish ,Chinese ,Pembrolizumab Keytruda ,Avelumab Bavencio ,Aino Kalervo ,Akseli Hemminki ,Timo Ahopelto ,Kostenloser Wertpapierhandel ,Tuija Keinonen ,Miia Kaye ,University Of Helsinki ,European Innovation Council ,Linkedin ,Pfizer Alliance ,Scius Communications ,Merck Kga ,Tesi Finnish Industry Investment Ltd ,Merck Kgaa ,Appoints Tuija Keinonen ,Lifeline Ventures ,Finnish Industry Investment Ltd ,Venture Founding Partner ,Investment Manager ,Business Finland ,Tilt ,Iotherapeutics ,Nnounces ,Dover ,Billion ,Financing ,Advance ,Ncology ,Immunotherapy ,Assets ,